Drugs / HC-7366
HC-7366
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07401875 | Mar 2026 → Nov 2027 expected | kidney cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06285890 | May 2024 → Dec 2027 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06234605 | Apr 2024 → Nov 2026 expected | renal cell carcinoma | HiberCell, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05121948 | Feb 2022 → Feb 2024 | bladder transitional cell carcinoma, clear cell renal carcinoma, colorectal cancer, head and neck squamous cell carcinoma +1 | HiberCell, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | HiberCell, Inc. | Results HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 When Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual Meeting hibercell.com ↗
Encouraging preliminary signals of efficacy for the higher dose combination cohorts of HC-7366 with belzutifan were observed. |
| 2026-04-14 | HiberCell, Inc. | Results HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC) hibercell.com ↗
The data further support HC-7366 as a potential strategy to overcome VEGFR-TKI resistance in metastatic ccRCC and provide rationale for clinical evaluation of HC-7366 and VEGFR-TKI combinations in ccRCC. |
| 2025-05-27 | HiberCell, Inc. | Results HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in Advanced ccRCC hibercell.com ↗
All three dose levels tested cleared the respective dose-limiting toxicity (DLT) evaluations. |
| 2023-03-27 | HiberCell, Inc. | Results HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 hibercell.com ↗
We will also present data on HC-7366, which have shown robust anti-tumor activity both as a monotherapy in and in combination with standard of care agents in several tumor types. |
| 2023-02-22 | HiberCell, Inc. | Results HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML) hibercell.com ↗
In vitro and in vivo results demonstrated HC-7366 is a potent GCN2 activator with strong antitumor activity in AML as a single agent and in combination with venetoclax; data supports further clinical development of HC-7366 as a treatment for AML |
| 2022-11-02 | HiberCell, Inc. | Results HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting hibercell.com ↗
Novel GCN2 modulator HC-7366 decreases pulmonary metastases and reduces myeloid-derived suppressor cells |
All press releases naming this drug 10 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HC-7366 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05121948 ↗ |
| Known as | HC-7366 potassium salt monohydrate | “HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration.” NCT05121948 ↗ |
| Known as | HC-7366-K | “HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration.” NCT05121948 ↗ |
| Action | Activate | “GCN2) kinase activator.” NCT06234605 ↗ |
| Route | Oral | “HC-7366 administered orally once a day” NCT05121948 ↗ |